Group One Trading’s Xeris Biopharma Holdings XERS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.09M Sell
218,709
-7,898
-3% -$66.7K ﹤0.01% 2100
2026
Q2
$1.79M Buy
226,607
+8,462
+4% +$54K ﹤0.01% 2322
2026
Q1
$1.27M Buy
218,145
+94,584
+77% +$627K ﹤0.01% 2485
2025
Q4
$970K Buy
123,561
+117,537
+1,951% +$925K ﹤0.01% 2920
2025
Q3
$49K Buy
+6,024
New +$40K ﹤0.01% 5984
2024
Q1
– Sell
-78,951
Closed -$204K – 8079
2023
Q4
$186K Buy
78,951
+12,781
+19% +$23.6K ﹤0.01% 3933
2023
Q3
$123K Buy
66,170
+26,097
+65% +$59.8K ﹤0.01% 4262
2023
Q2
$105K Sell
40,073
-55,785
-58% -$142K ﹤0.01% 4577
2023
Q1
$156K Buy
95,858
+41,851
+77% +$52.4K ﹤0.01% 3889
2022
Q4
$71.8K Buy
+54,007
New +$76.2K ﹤0.01% 4722
2020
Q3
– Sell
-2,180
Closed -$8.72K – 6603
2020
Q2
$6K Buy
2,180
+1,700
+354% +$5.92K ﹤0.01% 5327
2020
Q1
$1K Sell
480
-300
-38% -$1.29K ﹤0.01% 5118
2019
Q4
$6K Hold
780
– – ﹤0.01% 4728
2019
Q3
$8K Buy
+780
New +$8.76K ﹤0.01% 4659

Other funds holding XERS

Group One Trading's XERS Position: Q3 2026 in Review

Group One Trading reduced its Xeris Biopharma Holdings (XERS) stake by 3.5% in Q3 2026, selling an estimated $66.7K and leaving 218,709 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2100.

Group One Trading first reported a position in XERS in Q3 2019 and has held it in 14 quarters since. 248 funds tracked by Wall St. Rank hold XERS as of Q3 2026.

  • Group One Trading held 218,709 shares of Xeris Biopharma Holdings worth $2.09M as of Q3 2026.
  • Group One Trading sold 7,898 Xeris Biopharma Holdings shares in Q3 2026, an estimated $66.7K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #2100 holding.
  • Group One Trading first reported a position in Xeris Biopharma Holdings in Q3 2019 and has held it in 14 quarters since.
  • 248 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.